Curanex Pharmaceuticals Inc Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $133.6M
- Price
- $4.71
- % Change (Daily % change from the live per-ticker quote feed.)
- -10.63%
- Volume
- 28.6K
About
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Quick stats
Shares outstanding28.4M
Computed float456.1K
Float / shares1.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002025942
AI Summary
AI-generated1/8
minorneutrallegal litigation
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
Wolf Haldenstein Adler Freeman & Herz LLP announced an investigation into potential securities fraud on behalf of Curanex Pharmaceuticals Inc. shareholders.
The firm is investigating whether the company or its officers engaged in unlawful business practices, specifically regarding the period surrounding its recent IPO.
Investors who purchased shares and suffered losses are being solicited to contact the firm to discuss their rights.